Beam Expects BEAM-302 Pivotal Dosing Finish in First Half 2027

The Tip Desk · November 4, 2026 · 3 min read

The base-editing company ended the quarter with a $134.4 million net loss, or $1.28 a share, and $1.0 billion in cash as it moved toward a potential risto-cel BLA.

Beam Therapeutics Inc. (BEAM) reported a third-quarter 2026 net loss of $134.4 million, or $1.28 a share, as it advanced four clinical programs and said it expects to complete dosing in the global pivotal cohort of BEAM-302 in the first half of 2027.

The Cambridge, Massachusetts biotechnology company developing precision genetic medicines through base editing said the pivotal cohort, designed to support a potential accelerated approval path in the United States for alpha-1 antitrypsin deficiency, is still enrolling and dosing. Two quarters earlier the company had described that cohort as expected to initiate in the second half of 2026; in July it dosed the first pivotal patient.

In September, Beam presented updated Phase 1/2 data from BEAM-302 at the European Respiratory Society Congress. With up to 18 months of follow-up, the company said the data showed durable increases in total and functional AAT, decreased circulating neutrophil elastase activity, and reductions in mutant Z-AAT and toxic circulating Z-polymers after a single dose. It said evidence of AAT production under normal physiological control further supports the program’s potential to restore the body’s natural protective response, with a safety profile consistent with lipid nanoparticle-based therapies.

Hematology remained on a similar regulatory clock. Beam said it expects to report updated clinical data by year-end 2026 and submit a U.S. biologics license application for risto-cel in sickle cell disease as early as year-end 2026. Dosing had already been completed for all adult and adolescent patients in the BEACON trial in the prior quarter.

In phenylketonuria, Beam nominated a third base editor in BEAM-304 targeting a third undisclosed PAH mutation. Now encompassing three editors for distinct mutations, the company said the program has the potential to address up to 50% of PKU patients in the U.S. It continues clinical start-up for a Phase 1/2 trial that will initially evaluate safety, tolerability and reduction of blood phenylalanine levels in patients with the R408W mutation, with dosing expected in early 2027.

Initial BEAM-301 Phase 1/2 data presented at ESGCT in October showed dose-dependent improvements in time to fasting hypoglycemia across all patients. Two of three patients in the 40 mg cohort achieved the protocol-defined maximum controlled fasting duration of at least 15 hours and complete elimination of starch supplementation, the company said. Enrollment in a 60 mg cohort is underway, and Beam said it plans to engage the FDA regarding a potential path to approval.

License and collaboration revenue was $307 thousand in the three months ended September 30, 2026, compared with $9.7 million a year earlier. Research and development expenses were $110.1 million, essentially unchanged from $109.8 million in the year-ago quarter. General and administrative expenses were $31.5 million. The net loss widened from $112.6 million, or $1.10 a share, a year earlier.

Cash, cash equivalents and marketable securities were $1.0 billion as of September 30, 2026, compared with $1.2 billion at year-end 2025. Beam said that cash, together with an additional $200 million expected to be drawn from its Sixth Street facility, is expected to fund operating expenses and capital expenditure into mid-2029, assuming the conditions on those borrowings are met. The company said that runway is expected to support a potential launch of risto-cel, execution of the BEAM-302 pivotal plan, and clinical proof of concept for BEAM-304.

In September, Beam appointed Eric Foster as chief commercial officer to lead the commercial organization as hematology and genetic disease programs advance toward potential launches. Chief executive John Evans said the company is approaching a potential first BLA filing with risto-cel as early as the end of the year.